City of Hope opens first U.S. multicenter clinical trial for robotic single-port mastectomies for breast cancer patients

Bryan Burt named chief of thoracic surgery at UCLA Health

Surgeon and thoracic surgical oncologist Bryan Burt was named chief of thoracic surgery and professor of surgery at UCLA Health and the David Geffen School of Medicine at UCLA.

December 01, 2023

Vol.49 No.44

Drugs & Targets

FDA approves Truqap + fulvestrant for breast cancer

FDA approved Truqap (capivasertib) with fulvestrant for adult patients with hormone receptor-positive, human epidermal growth factor receptor-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

November 17, 2023

Vol.49 No.43

Conversation with The Cancer Letter

John Carpten: City of Hope’s national strategy drew me to this opportunity

John Carpten, when he was named director of the City of Hope Comprehensive Cancer Center in April, took over a massive, newly formed national oncology network—the first of its kind.

Alan Bryce named chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at TGen

Alan H. Bryce was named chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at Translational Genomics Research Institute (TGen), part of City of Hope.

November 10, 2023

Vol.49 No.42

In Brief

The Max Foundation provides targeted treatment for advanced breast cancer patients in Mozambique at no cost

Three patients in Mozambique have started treatment for HER2- HR+ advanced breast cancer, including CDK4/6 inhibitor therapy through The Max Foundation’s Max Access Solutions program.

November 10, 2023

Vol.49 No.42

Clinical Roundup

Phase III trial evaluating sotorasib + panitumumab: MCC patients with rare tumor mutation experienced superior PFS compared to standard of care

An international phase III clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab.

November 03, 2023

Vol.49 No.41

City of Hope opens first U.S. multicenter clinical trial for robotic single-port mastectomies for breast cancer patients

YOU MAY BE INTERESTED IN

Bryan Burt named chief of thoracic surgery at UCLA Health

FDA approves Truqap + fulvestrant for breast cancer

John Carpten: City of Hope’s national strategy drew me to this opportunity

Alan Bryce named chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at TGen

The Max Foundation provides targeted treatment for advanced breast cancer patients in Mozambique at no cost

Phase III trial evaluating sotorasib + panitumumab: MCC patients with rare tumor mutation experienced superior PFS compared to standard of care

Renew today!

Subscriber content

Login